US4287180A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating blood clotting factor inhibitors
Assignee: Baxter International Inc
•
Filing: 1980-01-28
•
Granted: 1981-09-01
•
Expires: 2000-01-28
Abstract
Abstract Compositions including, in units/ml, factor VIII correctional activity, about from 2-35; prothrombin, about from 1-10; thrombin, less than about 0.003; factor VII, about from 37-190; factor VIIa, about from 8-80; total factor IX, about from 15-112; factor IX precursor, 0 to about 30; factor X, about from 1-30; and factor Xa, about from 1-10 are used in therapeutically effective amounts to treat blood clotting factor inhibitors.
Inventors
- 👤 William R. Thomas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 15:13
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/647; C12N9/6429; C12Y; C12Y304/00; C12Y304/21; C12Y304/21005; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
80 words
A method for treating a patient having an inhibitor of a blood clotting factor, which comprises administering to the patient a therapeutically effective dose of an aqueous composition including, in units/ml, factor VIII correctional activity, about from 2-35; prothrombin, about from 1-10; thrombin, less than about 0.003; factor VII, about from 37-190; factor VIIa, about from 8-80; factor IX, about from 15-112; factor IX precursor, 0 to about 30; factor X, about from 1-30; and factor Xa, about from 1-10.
Claim 2
Independent Claim
80 words
A method for treating a patient having an inhibitor of a blood clotting factor, which comprises administering to the patient a therapeutically effective dose of an aqueous composition including, in units/ml, factor VIII correctional activity, about from 2-35; prothrombin, about from 1-10; thrombin, less than about 0.003; factor VII, about from 37-190; factor VIIa, about from 8-80; factor IX, about from 15-112; factor IX precursor, 0 to about 30; factor X, about from 1-30; and factor Xa, about from 1-10.
Claim 3
Dependent Claim
22 words
The method of claim 1 wherein the therapeutically effective dose is greater than about 25 factor VIII correctional units/kg of patient weight.
Claim 4
Independent Claim
17 words
The method of claims 1 wherein the aqueous composition additionally comprises greater than 1.1 units of heparin/ml.
Claim 5
Independent Claim
13 words
The method of claims 1 wherein the aqueous composition additionally comprises antithrombin III.
Claim 6
Independent Claim
28 words
The method of claims 1 wherein the aqueous composition is sufficiently free of factor VIII antigen to not provoke an immune response in the patient to factor VIII.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-08-31 | 1985-03-02 | 1985-09-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-08-31 | 1989-03-02 | 1989-09-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-08-31 | 1993-03-02 | 1993-09-01 | $7700.00 | Window Closed / Lapsed |